Neuroprotection in Parkinson Disease, Mysteries, Myths, and Misconceptions
JAMA 291:358-364, Schapira,A.H.V.&Olanow,C.W., 2004
[123I]b-CIT SPECT is a Useful Method for Monitoring Dopaminergic Degeneration in Early Stage Parkinson's Disease
JNNP 74:294-298,287, Winogrodzka,A.,et al, 2003
Ischemic Core and Penumbra in Human Stroke
Stroke 30:93-99, Kaufmann,A.M.,et al, 1999
Characterizing the Target of Acute Stroke Therapy
Stroke 28:866-872, Fisher,M., 1997
Therapeutic Hypothermia for Global and Focal Ischemic Brain Injury-A Cool Way to Improve Neurologic Outcomes
Neurologist 13:331-342, Hoesch,R.E. &Geocadin,R., 2007
Guidelines for the Early Management of Patients with Ischemic Stroke
Stroke 36:916-921, Adams,H.,et al, 2005
New Imaging Strategies for Patient Selection for Thrombolytic and Neuroprotective Therapies
Neurol 57:S48-S52, Warach,S., 2001
HMG-CoA Reductase Inhibitors (Statins)
Neurol 54:790-795, Hess,D.C.,et al, 2000
Head Injury
JNNP 56:440-447, Miller,J.D., 1993
Do NMDA Antagonists Prevent Neuronal Injury? Yes
ARch Neurol 49:418-420, Albers,G.W.,et al, 1992
Do NMDA Antagonists Prevent Neuronal Injury? No
Arch Neurol 49:420-421, Buchan,A.M., 1992